伊马替尼治疗进展期胃肠间质瘤的临床疗效观察.docVIP

伊马替尼治疗进展期胃肠间质瘤的临床疗效观察 　　摘要：目的：观察伊马替尼治疗进展期胃肠间质瘤的临床疗效，并分析主要的影响因素。方法：选取2008年1月-2011年1月期间我院收治的52例进展期胃肠间质瘤患者作为研究对象，回顾性分析所有患者的临床资料，且所有患者均进行了伊马替尼治疗，分析治疗后的疗效及影响治疗效果的因素。结果：所有进展期胃肠间质瘤患者均进行了伊马替尼的治疗，完全缓解的患者有1例，部分缓解的患者有37例，疾病得到稳定的有10例，疾病进展有4例，总有效率为92.31%；所有患者均进行6个月-32个月的随访， 52例患者中死亡人数为4例，其中有2例患者在口服伊马替尼治疗中死亡，所有死亡患者均在疾病进展中死亡。结论：本次分析结果表明基因突变和治疗前体力评分对伊马替尼的疗效有一定的影响，且伊马替尼在临床上治疗胃肠间质瘤具有显著的疗效，已经得到广泛的应用。 　　关键词：伊马替尼；胃肠间质瘤；临床疗效；影响因素 　　Abstract：Objective： To observe the imatinib in treatment of advanced gastrointestinal stromal tumors clinical efficacy， and analysis of the main influence factors. Methods： from 2008 January -2011 year during January were treated in our hospital in 52 patients with advanced gastrointestinal stromal tumor patients as the object of study， a retrospective analysis of clinical data of all patients， and all patients were treated with imatinib after treatment， analysis of effect and influencing factors of therapeutic effect. Results： all advances in perioperative patients with gastrointestinal stromal tumors were evaluated by imatinib treatment， complete remission in patients with 1 cases， partial remission in patients with 37 cases， the disease was stable in 10 cases， the progression of the disease in 4 cases， the total effective rate was 92.31%； all the patients underwent 6 months of -32 months follow-up， 52 patients died in 4 patients， including 2 patients in the oral imatinib therapy in all patients were death， death in disease progression in death. Conclusions： the results show that gene mutations and treatment before physical score on the efficacy of imatinib has certain effect， and imatinib in treatment of gastrointestinal stromal tumors with distinct curative effect， has obtained the widespread application. 　　【中图分类号】R73 【文献标识码】B 【文章编号】1674-7526（2012）12-0353-02 　　胃肠间质瘤简称GIST，在胃肠道中是较为常见的肿瘤，其首选治疗方案为外科手术。但是术后复发率发生较高，且复发的患者多数为肝脏或腹腔多发性转移。若是选择放化疗进行治疗，胃肠间质瘤细胞对其并不敏感。相关研究资料表明，伊马替尼在治疗胃肠晚期间质瘤时可使患者生存期延长10-20个月，伊马替尼无论是从体内进行治疗还是体外进行治疗，均具有显著的疗效，有效的延长患者存活时间，长达36个月-5